AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...
Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...
AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...
INSEMA and SOUND are among four trials designed to evaluate omission of SLNB in patients with clinically node-negative early ...
AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...
Medpage Today on MSN20h
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast CancerAmong more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or ...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback